Zephyrm Bioscience

Executive Summary

Zephyrm Bioscience is a preclinical-stage biotechnology company based in Suzhou, China, focused on discovering and developing novel therapeutic antibodies for oncology and immunology. Leveraging proprietary antibody engineering platforms, the company aims to create biologics that modulate the immune system to treat cancer and autoimmune disorders. Founded in 2020, Zephyrm operates with a lean team of 1-50 employees and remains privately held. Though still in early stages, the company's strategic focus on immune-modulating antibodies positions it within a competitive but high-potential space. Key upcoming milestones include advancing lead candidates toward Investigational New Drug (IND) filing and initiating first-in-human studies.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Oncology Candidate40% success
• Q1 2027First-in-Human Trial Initiation30% success
• TBDPartnership or Licensing Deal25% success